Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGFBR-2 KO CD70 CAR NK Cells in Advanced Clear Cell Renal Cell Carcinoma
NCT07072234Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2025
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of TGFBR2 KO CAR.70/IL-15 NK cells in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events at 1 year. Started Sep 2025; status: recruiting.
02
Drugs
TGFBR2 KO CAR.70/IL-15 NK cells
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07072234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072234.